GLP-1 Medications Have Become a Line-Item Issue Over the past year or so, GLP-1 drugs have shifted from clinical innovation to a major budget concern
doi: 10.3389/fnut.2024.1509577 Received 11 October 2024 Accepted 02 December 2024 Published 16 December 2024 Volume 11 - 2024 Edited by Shaohua Qi, Houston Methodist Research Institute, United States Reviewed by Ying-yuan Lu, Peking University, China Ma Ying, China Academy of Chinese Medical Sciences, China Kexin Gai, Northwestern University, United States Ting Wu, University of Texas Health Science Center at Houston, United States Updates Copyright 2024 Xing, Du, Li, Wang, Zhang, Gao, Han, Sun, Sun, Du, Hu, Yu and Qin
GLP-1RA intervention was not associated with increased dizziness events when compared to those given metformin or placebo (OR = 1.20
Its important to understand the potential risks and benefits before deciding whether or not to pursue skin lightening
ACS Omega 5 , 29672977 (2020)
REPATHA (evolocumab) Manufactured by: Amgen Inc